{"organizations": [], "uuid": "950dd715aece44542e57986995ce5ae2790e5be8", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180409.html", "section_title": "Archive News &amp; Video for Monday, 09 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-vtv-therapeutics-announces-topline/brief-vtv-therapeutics-announces-topline-results-from-the-first-steadfast-phase-3-study-evaluating-azeliragon-in-people-with-mild-alzheimers-disease-idUSFWN1RM0R5", "country": "US", "domain_rank": 408, "title": "BRIEF-Vtv Therapeutics Announces Topline Results From The First Steadfast Phase 3 Study Evaluating Azeliragon In People With Mild Alzheimer's Disease", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 1.0, "site_type": "news", "published": "2018-04-10T04:52:00.000+03:00", "replies_count": 0, "uuid": "950dd715aece44542e57986995ce5ae2790e5be8"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-vtv-therapeutics-announces-topline/brief-vtv-therapeutics-announces-topline-results-from-the-first-steadfast-phase-3-study-evaluating-azeliragon-in-people-with-mild-alzheimers-disease-idUSFWN1RM0R5", "ord_in_thread": 0, "title": "BRIEF-Vtv Therapeutics Announces Topline Results From The First Steadfast Phase 3 Study Evaluating Azeliragon In People With Mild Alzheimer's Disease", "locations": [], "entities": {"persons": [{"name": "alzheimer", "sentiment": "none"}, {"name": "azeliragon", "sentiment": "none"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "neutral"}, {"name": "therapeutics inc", "sentiment": "neutral"}, {"name": "vtv therapeutics inc", "sentiment": "none"}, {"name": "vtv therapeutics", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 9 (Reuters) - vTv Therapeutics Inc:\n* VTV THERAPEUTICS ANNOUNCES TOPLINE RESULTS FROM THE FIRST STEADFAST PHASE 3 STUDY EVALUATING AZELIRAGON IN PEOPLE WITH MILD ALZHEIMER’S DISEASE\n* VTV THERAPEUTICS INC - AZELIRAGON WAS GENERALLY WELL-TOLERATED IN STUDY\n* VTV THERAPEUTICS INC - PHASE 3 STEADFAST STUDY DID NOT MEET EITHER CO-PRIMARY EFFICACY ENDPOINT\n* VTV THERAPEUTICS - IS DISCONTINUING CURRENT CLINICAL STUDIES INVOLVING AZELIRAGON, INCLUDING OPEN-LABEL EXTENSION STUDY AND PART B OF STEADFAST STUDY​\n* VTV THERAPEUTICS - WILL CONTINUE TO EVALUATE SUBSET DATA FROM PART A AND DATASET FROM PART B OF STEADFAST STUDY OVER COMING WEEKS\n* VTV THERAPEUTICS - EXPECT SUBSTANTIAL PORTION OF PATIENTS IN PART B OF STEADFAST WILL HAVE COMPLETED 12 MONTHS OF TREATMENT UNDER STUDY PROTOCOL Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-10T04:52:00.000+03:00", "crawled": "2018-04-10T13:00:51.036+03:00", "highlightTitle": ""}